What is Red Queen Bio?
Red Queen Bio operates at the intersection of artificial intelligence and biological defense, specializing in the identification and mitigation of rapidly evolving biological risks. The company utilizes frontier AI models and sophisticated lab automation to map potential biothreats, effectively creating a scalable framework for countermeasure design. By bridging the gap between high-level policy and technical execution, the firm provides essential tools for labs and government entities to bolster global safety and resilience.
The company's market position is defined by its unique approach to proactive defense. Rather than reacting to biological incidents, Red Queen Bio focuses on predictive modeling and rapid response capabilities. This strategic focus on deep tech and translational science allows the firm to address systemic vulnerabilities in global health security, making it a vital partner for policymakers and scientific institutions alike.
How much funding has Red Queen Bio raised?
Red Queen Bio has raised a total of $15M across 1 funding round:
Seed
$15M
Seed (2025): $15M with participation from Halcyon Futures, Fifty Years, OpenAI, and Cerberus
Key Investors in Red Queen Bio
Halcyon Futures
Halcyon Futures is a mission-driven firm that provides seed capital and operational support to leaders building transformative AI and resilient technologies.
Fifty Years
Fifty Years is a venture capital firm specializing in deep tech and translational science, supporting founders who address global challenges like disease and climate change.
OpenAI
OpenAI is a leading AI research organization focused on developing safe and beneficial artificial general intelligence through advanced large language models and deployment tools.
What's next for Red Queen Bio?
With the recent infusion of capital, Red Queen Bio is set to expand its operational footprint and enhance its proprietary AI platforms. The company's roadmap includes scaling its automated laboratory infrastructure and deepening its collaboration with international stakeholders to refine its biothreat detection protocols. As it moves forward, the firm will likely focus on the commercialization of its countermeasure design tools, aiming to establish a new standard for biosecurity preparedness in an era of increasing biological complexity.
The strategic deployment of these funds will also facilitate the recruitment of top-tier talent in computational biology and machine learning, further strengthening the company's competitive advantage. By maintaining a focus on responsible innovation and safety, Red Queen Bio is well-positioned to navigate the regulatory landscape while delivering high-impact solutions to the most pressing challenges in global health.
